I t is estimated that 2-3 million people in the United States are infected with chronic hepatitis C virus (HCV).
1 HCV has been the most common indication for liver transplantation (LT) in North America and Western Europe for the last 20 years. [2] [3] [4] Chronic HCV infection can necessitate LT through 2 main mechanisms: chronic liver failure (CLF) manifesting as synthetic dysfunction and complications of portal hypertension (ie, ascites) and hepatocellular carcinoma (HCC).
Since 2011, the landscape of HCV treatment has evolved rapidly, with the sequential approval by the US Food and Drug Administration of 6 direct-acting antiviral agents (DAAs) with progressive advances in efficacy and, as importantly, tolerability. The NS3/4A HCV protease inhibitors telaprevir 5 and boceprevir 6 were the first DAAs to be approved in 2011. DrugÀdrug interactions, toxicities of these medications, and the need to co-administer interferon, greatly limited the utility and impact of these agents in patients with advanced liver disease. The therapeutic landscape was altered again in December 2013, when the US Food and Drug Administration approved 2 new agents: sofosbuvir 7 and simeprevir, 8 with efficacy against HCV genotype 1. The safety and efficacy of sofosbuvir and simeprevir, together and independently, among patients with cirrhosis has been documented in several multicenter studies, with cure rates exceeding 90%. [9] [10] [11] Recent studies have demonstrated similar cure rates in patients with moresevere liver disease, including patients with Child-TurcottePugh (CTP) classification B and C stages of disease, yielding improvements or stabilization in liver disease, as measured by the Model for End-Stage Liver Disease (MELD) and CTP scores in the great majority of treated patients. 12, 13 The reported improvement in MELD and CTP scores among treated patients with advanced liver disease suggest that the advent of highly effective and well-tolerated DAAs clearly could, in theory, reduce the frequency of HCV and HCVrelated complications in the general population and, as a result, as an indication for LT. Such an effect has not been reported to date. Furthermore, it is possible that the impact of treatment with DAAs may differentially affect waitlist additions and LT for HCV for CLF, as cure can lead to immediate stabilization or improvement in liver function, as compared with HCC, which would have a more delayed benefit in the broader HCV population, and those with more advanced disease.
Concurrent to rapid advancements in the treatment of HCV, the incidence of liver failure and HCC related to nonalcoholic fatty liver disease (NAFLD) have been reported to be increasing dramatically, 14 with associated increases in the prevalence of NAFLD-related liver disease as an indication for LT. 15 In addition to the impact of improved therapy for HCV and the steady increase in the frequency of NAFLD and as a cause of liver failure and HCC, alcoholrelated liver disease (ALD) has been reported as the most common cause of chronic liver disease, rather than HCV or NAFLD, 16 with recent evidence that LT for acute alcoholic hepatitis (which almost always occur in the setting of advanced fibrosis) confers substantial survival benefits, with a low frequency of relapse of clinically apparent alcohol use after LT in carefully selected patients. The impact of these 3 emerging trends on the overall need for, and relative frequency of, indications for LT is likely to be substantial, but must be weighed in the face of recently published data suggesting that patients with liver disease related to NAFLD or ALD are significantly less likely to be waitlisted compared to patients with HCV, and patients with cirrhosis complicated by HCC are 2-5 times more likely than patients with CLF. 17 We sought to assess the impact of new advents in HCV treatment and emerging trends in liver disease in the broader population with cirrhosis and the more limited waitlist population, we sought to synthesize data from 3 distinct data sets. We evaluated data from the National Health and Nutrition Evaluation Survey (NHANES) from a nationally representative database that includes a broad cohort of patients with cirrhosis, and national transplantation data from 2003 to 2015. In combining data from these 3 data sets, our overarching goal was to evaluate temporal trends in the burden of liver disease from HCV, NASH, and ALD through the continuum of liver disease: chronic liver disease/compensated cirrhosis/CLF (decompensated cirrhosis) and HCC/waitlisting for transplantation/transplantation.
Materials and Methods

Population-Based Data on the Changing Epidemiology of Chronic Hepatitis C Virus
We first sought to assess changes in the prevalence of chronic HCV in the era of DAA therapy using NHANES data from the 2013-2014 cycle. The details on NHANES methods and procedures have been published previously. 1 The NHANES collects nationally representative data on the noninstitutionalized US civilian population. 18 With respect to HCV, all individuals 6 years and older are tested for the presence of antibodies to HCV (anti-HCV). Individuals testing HCV positive undergo further testing with HCV RNA and, if positive, HCV genotype. There were no changes to the laboratory method, laboratory equipment, or laboratory site for hepatitis C RNA and hepatitis C genotype in the NHANES 2013-2014 cycle compared to the previous NHANES survey cycles.
Population-Based Data on Compensated Cirrhosis, Chronic Liver Failure, and Hepatocellular Carcinoma The next step in the pathway from chronic liver disease to end-stage liver disease is the development of cirrhosis, followed by either decompensated cirrhosis (CLF) or HCC. In order to evaluate temporal trends in the etiologies of liver disease for cirrhosis and advanced liver disease, we assessed the burden of cirrhosis from HCV, ALD, and NASH using HealthCore Integrated Research Database (HIRD), a nationally representative database of commercially insured patients, from 2006 to 2014. HealthCore is a wholly owned subsidiary of Anthem, Inc, serving members in all 50 states. It is a nationally representative data set of commercially insured patients, with longitudinal medical and pharmacy claims on 25 million patients, and has been used for prior studies evaluating population-level outcomes in patients with CLF and HCC. 17, [19] [20] [21] This study sample has been described previously.
17,21 HIRD patients with cirrhosis were categorized as compensated cirrhosis, CLF, or HCC. These categories were based on severity of cirrhosis at entry into the study cohort, and were defined using algorithms based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes that have been validated to have positive predictive values of >85%. [22] [23] [24] [25] [26] Using HIRD data enabled us to estimate the emerging trends in cirrhosis and advanced liver disease from HCV, ALD, and NASH.
Compensated cirrhosis was defined based on having !1 inpatient or !2 outpatient ICD-9-CM codes for cirrhosis (571.2, 571.5) in the absence of a complication of portal hypertension, HCC, or laboratory abnormalities consistent with severe liver synthetic dysfunction (MELD score !15 and/or total serum bilirubin !3 mg/dL). [22] [23] [24] [25] [26] CLF was defined as having !1 inpatient or !2 outpatient ICD-9-CM codes for a complication of portal hypertension (ascites, bleeding esophageal varices, ascites, and/or spontaneous bacterial peritonitis) occurring after the diagnosis of cirrhosis. HCC required a diagnosis of cirrhosis and !1 inpatient or !2 outpatient ICD-9-CM code for HCC (ICD-9-CM code: 155.0). In the subset of cirrhotic patients without HCC or a complication of portal hypertension, we used laboratory criteria to define hepatocellular dysfunction/CLF (calculated MELD score !15 and/or a total serum bilirubin !3 mg/dL.) Although this cohort may not fully reflect the entire US population, it was a uniform cohort over time that allowed us to evaluate trends in cirrhosis, CLF, and HCC in a broader population with chronic liver disease. Etiology of liver disease was based on ICD-9-CM coding for patients with HCV or ALD (patients with HCV and ALD were categorized as HCV). NASH was assigned as the etiology of liver disease in patients without a specific etiology of liver disease based on ICD-9-CM codes in the setting of !1 of the following: ICD-9-CM code for obesity/ overweight, diabetes mellitus, impaired glucose tolerance, hyperlipidemia, hypertension, or a hemoglobin A1c !6.5%, if such laboratory data were available. Patients were required to have at least 90 days of complete follow-up in the HIRD in order to be included in the study. Of note, the HIRD does include patients with certain Medicare Advantage plans, but this represents <5% of patients, and in our HIRD population, only 44.6% were 65 years of age or older.
Waitlist and Transplanation Data
The final pathway of advanced liver disease is waitlisting for transplantation, and transplantation in the sickest patients with chronic liver disease. To assess this, we performed analyses using Organ Procurement and Transplantation Network (OPTN)/ United Network for Organ Sharing (UNOS) data. For analyses of new waitlistings, we included all adult patients (18 years of age and older) added to the waiting list between February 27, 2002 and December 31, 2015. Patients listed for retransplantation and/or listed after being removed from the waitlist were included. For transplant analyses, we included all adult (18 years of age and older) transplant recipients between February 27, 2002 and December 31, 2015, including retransplantation patients. All new waitlistings and transplant recipients with acute liver failure and/or status 1 designation were excluded in order to identify a cohort with chronic liver disease.
Etiology of liver disease was based on OPTN/UNOS diagnostic coding, HCV serostatus data, and free texting of diagnoses for patients without a specified diagnosis based on OPTN/UNOS coding. Relistings or retransplantation recipients were assigned an etiology of liver disease based on coding for the initial transplantation. Patients were then categorized into the 3 main etiologies of liver disease (HCV, ALD, NASH/cryptogenic), with the remaining patients categorized as "other." Analyses were stratified into transplant recipients with CLF (including decompensated cirrhosis and other manifestations of chronic liver disease excluding status 1) and HCC (based on diagnostic codes and HCC exception points) to evaluate differences in indications for transplantations for patients with CLF vs HCC.
Statistical Analysis of National Health and Nutrition Evaluation Survey Data
We used appropriate published sampling weights as recommended by the NCHS for the NHANES survey. To determine if any change in prevalence may be attributable to treatment effect, we compared the proportion of HCV RNA-to-HCV antibodies in 2010 and 2014, knowing that drugs only affect HCV RNA but not HCV antibodies. These proportions were compared using the c 2 test.
Statistical Analyses of Organ Procurement and Transplantation Network/United Network for Organ Sharing Data
We first evaluated the absolute number of new waitlistings and transplant recipients by disease category, stratified by CLF vs HCC. For each calendar year, we then calculated the percentage of new waitlisting and transplant recipients with vs without HCV, stratified by indication for transplantation. We first tested whether the percentage of new waitlistings and transplant recipients with HCC within each category (CLF vs HCC) were significantly different; such statistical tests assessed whether the percentage with vs without HCC differed among the 14 calendar years. To then test for statistical trends over time (rather than differences in percentage but temporal trends), we evaluated the percentage of new waitlistings and transplant recipients with HCV stratified by indication for transplantation, modeling calendar year as a continuous variable, in 3 ways: Spearman rank correlation with the dependent variable as the percentage of within a specified category with HCV and the independent variable being calendar year; nonparametric test of trends; and linear regression models with the outcome of percentage within a specified category with HCV and the exposure calendar year as a continuous variable. All analyses were performed using STATA, version 14.0 (College Station, TX).
Results
Burden of Chronic Hepatitis C Virus in the Population
There were 8,291 subjects included in the 2010-2014 NHANES analysis. The median age was 35 years (interquartile range, 16-56 years), and a majority of subjects were female (51.5%) and non-Hispanic white (63.2%). HCV RNA was detectable in the serum of 67 study participants, which yielded a weighted prevalence of 0.65% (95% con- Of the 24,258 patients in the HIRD with compensated cirrhosis, 5,806 (23.9%) had HCV, 5,708 (23.5%) had ALD, and 3,521 (14.5%) had possible NASH (based on having no specific liver diagnosis in the setting of evidence for a medical or metabolic risk factor for NASH). An additional 6,731 (27.8%) patients with compensated cirrhosis had no identifying etiology of cirrhosis (cryptogenic cirrhosis), and no medical comorbidities that allowed us to say the patient had possible NASH with a high degree of confidence. Among the 14,971 patients with CLF, 4,007 (26.8%) had HCV, 6,469 (43.2%) had ALD, and 2,474 (16.5%) had presumed NASH. Among the 1,853 patients with cirrhosis and HCC, 1,138 (61.4%) had HCV, 329 (17.8%) had ALD, and 187 (10.1%) had presumed NASH. There were temporal changes in the distribution of these diagnoses within each category: (1) compensated cirrhosis-decrease in the percentage with HCV and ALD in the face of increasing NASH ( Figure 1A) ; (2) CLF-decreased HCV and ALD with a near tripling in the percentage of these patients having NASH to the point that the percentage with HCV and presume NASH cross in calendar year 2014 ( Figure 1B) ; and (3) HCC-decreases in the percentage with HCV and ALD and a small increase with NASH ( Figure 1C ).
Waitlist and Transplantation Data
We evaluated the final pathway in the continuum from chronic liver disease to CLF and HCC severe enough to require a transplantation using OPTN data from February 27, 2002 through December 31, 2015. During this period, there was an absolute increase in the number of new waitlistings for LT and the number of liver transplants. Among new waitlistings with CLF, the absolute number with HCV was stable between 2004 and 2012, and then precipitously dropped over the next 3 calendar years (Figure 2A) . At the same time, there was a progressive, continued increase in the absolute number of new waitlistings with ALD and NASH/cryptogenic cirrhosis. By contrast, the absolute number of new waitlistings for HCC increased dramatically for patients with HCV between 2002 and 2014, and only increased modestly for other causes of liver disease ( Figure 2B ).
There was a significant difference in the percentage of new waitlistings for CLF who had HCV across the 14 calendar years (P < .001; Table 1, Figure 2C ). This manifested in a significant decrease in the percentage of new waitlistings with HCV among patients with CLF in all 3 statistical tests of trends (Table 1) . By contrast, among patients with HCC, despite there being a statistically significant difference in the percentage with HCV across the study period (P ¼ .008), there was no statistical trend in the percentage of new HCC waitlistings with HCV relative to increasing calendar year (Table 1 ; Figure 2D ).
There was a rise in the absolute number of transplantations for CLF in patients with HCV from 2002 to 2006, with a progressive decrease in the absolute number from 2007 to 2015 ( Figure 3A ). This decrease between 2007 and 2015 corresponded to an increase in the absolute number of LTs for CLF in patients with ALD and NASH/cryptogenic cirrhosis. Among transplant recipients with HCC, there was a steady linear increase in the absolute number of transplantations for HCC among patients with HCC, with a small increase in the absolute number among the other 3 diagnostic categories ( Figure 3B ).
There was a significant difference in the percentage of HCC transplant recipients with HCV across the study period (P < .001; Table 1, Figure 3C ). Curing the study period, all 3 tests of trends demonstrated a significant decrease in the percentage of CLF transplant recipients with HCV (Table 1) . By contrast, among HCC transplant recipients, there was not a statistically significant difference in the percentage with HCV across the study period (P ¼ .20). Despite this, there was a statistically significant trend over time, with an increase in the percentage of HCC transplant recipients with HCV relative to increasing calendar year (Table 1 ; Figure 3D ). 
Utilization of Livers from Hepatitis C VirusÀPositive Donors
New Prescriptions for Hepatitis C Virus Therapy in Medicare Beneficiaries
Data on the total number of prescriptions for DAAs in the broader population are not available, and are proprietary data by each drug manufacturer. However, there are publicly available data on the number of prescriptions for all medications for Medicare beneficiaries with Part D prescription coverage (approximately 70% of Medicare beneficiaries). These data demonstrate that between 2011 and 2013, the number of HCV prescriptions was stable; yet between 2013 and 2015, the number of prescriptions for DAAs increased by a factor of 5, which correlated with the time period that there were decreasing numbers of patients waitlisted and transplanted for CLF in the setting of HCV (Supplementary Figure 1) .
Discussion
By using 3 distinct databases, we have demonstrated dramatically changing trends in etiologies of chronic liver disease and CLF, which are associated with profound changes in the frequency of HCV, NASH, and ALD as indications for LT. The NHANES data clearly demonstrates that the burden of active HCV infection has decreased since the introduction of highly efficacious DAA therapy. Concurrent to advances in HCV treatment that allow for high cure rates, even in the setting of cirrhosis, is reflected by a decreased incidence of cirrhosis related to HCV (compensated or decompensated) in the broader population with chronic liver disease. Simultaneous to the decrease in the burden of cirrhosis from HCV, there has been an increase in the burden related to NASH to a degree almost as great as the decline for HCV, occurring parallel to the well-described increase in prevalence of obesity. Finally, when waitlisting and transplantation data were evaluated, there was a decreased burden of CLF due to HCV, which mirrors the data on the decreased prevalence of chronic HCV in the NHANES data and cirrhosis and CLF from HCV in the HIRD. At the same time, HCC waitlistings related to HCV increased, which likely reflects that even when patients with HCV and cirrhosis are treated, the benefit on HCC is more delayed. Parallel to the changes in HCV in the cirrhotic population, we saw increased waitlistings and transplantations for NASH, which reflects the increasing burden of NASH in the broader population with compensated cirrhosis and CLF. For reasons that are less clear, the frequency of LT for ALD has increased even more rapidly than that for NASH. This is even more striking because among cirrhotic patients with Medicaid or commercial health insurance, those with ALD are significantly less likely to be waitlisted than patients 
with HCV. 17 This fact, which will be discussed, likely reflects changes in behavior and attitudes with respect to waitlisting and transplantation for patients with ALD. All of these emerging trends have changed the face of chronic liver disease, cirrhosis, CLF, and LT in the United States.
Chronic liver disease due to HCV, NASH, or ALD occurs over many years, with continued liver damage and inflammation leading to fibrosis and progressive liver failure. For patients with ALD, there is the potential for rapid improvement in liver function with alcohol cessation, even in the setting of advanced fibrosis or cirrhosis. For HCV and NASH, it is clear that fibrosis can regress in the early stages of disease, but improvements in liver function are more modest in the presence of advanced disease. For these reasons, interventions to prevent disease before cirrhosis has developed are critical. Given the high costs of DAA therapy, therapy with DAAs was initially targeted toward patients with advanced fibrosis/ cirrhosis to prevent disease progression and decompensated liver disease. 27 Over time, patients at both ends of the spectrum (early-stage disease and CLF) have been considered for therapy. These data would suggest that with the advent of improved HCV treatments, the burden of HCV has decreased (NHANES data), leading to fewer patients with cirrhosis and/or decompensated cirrhosis (HIRD), and ultimately, fewer patients waitlisted and/or transplanted for CLF due to HCV (UNOS data). For these reasons, continuing efforts to diagnose HCV in those who are unaware of their diagnoses, and treating their HCV upon diagnosis are needed. An element of reversibility of severity of liver disease after successful DAA therapy in patients with decompensated liver disease due to HCV infection has been demonstrated recently in large, prospective studies. 28, 29 More than 75% of patients with decompensated cirrhosis who achieve a sustained virologic response experience a decline in MELD and CTP within the first 3 months after completion of DAA therapy. It is plausible that some part of the dramatic decline in waitlisting and transplantation for liver failure secondary to HCV is on the basis of treating patients with more advanced liver disease. 28, 29 Changes in waitlistings and transplantations for HCC have been much more modest than those observed for liver failure secondary to chronic HCV infection. This is not unexpected because hepatic fibrosis regression occurs over a process of many years and because the need for LT due to HCC is independent of intrinsic liver disease, such as indicated by the calculated MELD score. This underscores the fact that even if HCV is cured, continued HCC surveillance is needed in patients with HCV cirrhosis. Furthermore, even though advances in HCV treatment, even in the setting of cirrhosis, will be expected to continue to decrease the need for transplantation for CLF due to HCV, we should not expect HCV to disappear as a major indication for transplantation until efforts continue to focus on treating patients with HCV before advanced fibrosis has developed. It is worth noting that although the proportion of patients with HCC who had HCV in the HIRD cohort decreased over time, the proportion waitlisted for HCC in the setting of HCC increased. The data do not allow us to determine the exact reason for this, but it may simply be due to the fact that the relative proportion of HCCs due to HCV are so much higher in the setting of where these patients are preferentially listed that more patients with HCV are waitlisted. Second, it also may reflect the small sample size of HCC patients in HIRD on a year-to-year basis. Third, it may be that there is a lag between HCC diagnosis and subsequently being placed on the waitlist such that the changes in HCC listings relative to HCV may lag behind that in the general cirrhotic population.
There have been several previous reports describing the epidemic of NASH in the United States. The increased burden of NASH in the overall population is reflected by the increasing percentage of patients with cirrhosis (compensated or decompensated cirrhosis in the HIRD) due to NASH. Not surprisingly, this has translated to an increased proportion of new waitlistings for liver transplant, and actual transplants in the setting of NASH (although this may reflect greater awareness and labeling of NASH, it does reflect the rising prevalence of obesity and NASH in the general population). These population and waitlisting trends are all consistent with one another. The same cannot be said for ALD. In the broader population (HIRD), the percentage of patients with compensated cirrhosis, decompensated cirrhosis, or HCC who have ALD has decreased over time. As a result, one would have expected fewer waitlistings and transplantations due to ALD. However, this was not the case. The percentage of new waitlistings and transplantations for ALD has mirrored that of NASH, despite a decreasing overall prevalence in the general population. This speaks to changes in selection criteria for waitlisting and transplanting patients with ALD, rather than a growing burden of ALD. We do not think these changes in waitlist reflect broader temporal trends in improvement in alcohol abstinence rates. Although there was a highly publicized randomized controlled trial of baclofen therapy as a pharmacologic means to cause sustained abstinence, 30 this has not led to widespread use. Furthermore, there are data from the transplantation field that alcohol abstinence and recidivism rates are unchanged, with as many as 25% of waitlisted patients with alcohol-induced liver disease continuing to drink while waitlisted. 31, 32 Lastly, there have been other failed clinical trials for medications, such as selective serotonin reuptake inhibitors (ie, citalopram), to help with alcohol abstinence, 33 which all together would suggest changes in waitlisting for ALD reflect selection criteria for waitlisting rather than changes in abstinence rates for ALD.
This study has limitations. First, the NHANES data only captured HCV prevalence in a random subset of the US population, excluding populations that may be enriched with HCV without access to care (ie, homeless, incarcerated). This can lead to an underestimate of the burden of HCV, but this sampling in NHANES has been constant over time so would not explain the temporal changes we noted. Furthermore, the NHANES data does not include patients with NASH and/or ALD. Second, the data on the broader population with cirrhosis was based on patients with commercial health insurance, and may not generalize to patients with government-sponsored health insurance.
In conclusion, this analysis of multiple different data sets highlights novel trends in the burden of chronic liver disease. Chronic HCV seems to be decreasing with the advent of new therapies, which is manifesting as a lower burden of cirrhosis and CLF among waitlist additions and new transplant recipients. At the same time, NASH and ALD are becoming relatively more common among waitlisted patients and transplant recipients, despite different relative burdens of disease in the broader cirrhotic population.
